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Abstract
Background: Aristolochic acid (AA) is the active component of herbal drugs derived from Aristolochia
species that have been used for medicinal purposes since antiquity. AA, however, induced nephropathy
and urothelial cancer in people and malignant tumors in the kidney and urinary tract of rodents. Although
AA is bioactivated in both kidney and liver, it only induces tumors in kidney. To evaluate whether
microarray analysis can be used for distinguishing the tissue-specific carcinogenicity of AA, we examined
gene expression profiles in kidney and liver of rats treated with carcinogenic doses of AA.
Results: Microarray analysis was performed using the Rat Genome Survey Microarray and data analysis
was carried out within ArrayTrack software. Principal components analysis and hierarchical cluster analysis
of the expression profiles showed that samples were grouped together according to the tissues and
treatments. The gene expression profiles were significantly altered by AA treatment in both kidney and
liver (p < 0.01; fold change > 1.5). Functional analysis with Ingenuity Pathways Analysis showed that there
were many more significantly altered genes involved in cancer-related pathways in kidney than in liver.
Also, analysis with Gene Ontology for Functional Analysis (GOFFA) software indicated that the biological
processes related to defense response, apoptosis and immune response were significantly altered by AA
exposure in kidney, but not in liver.
Conclusion: Our results suggest that microarray analysis is a useful tool for detecting AA exposure; that
analysis of the gene expression profiles can define the differential responses to toxicity and carcinogenicity
of AA from kidney and liver; and that significant alteration of genes associated with defense response,
apoptosis and immune response in kidney, but not in liver, may be responsible for the tissue-specific
toxicity and carcinogenicity of AA.
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Background
Aristolochic acid (AA) is an active component of herbal
drugs derived from Aristolochia  species that have been
used for medicinal purposes since antiquity. The herbal
drugs containing AA were used for treatment of snake
bites, arthritis, gout, rheumatism and festering wounds, as
well as used in obstetrics [1]. This compound, however, is
a nephrotoxin and carcinogen. A progressive form of renal
fibrosis is associated with patients taking weight-reducing
pills containing AA [2-4]. The aristolochic acid nephropa-
thy was initially observed in Belgium in 1991 and about
half of the patients had renal replacement therapy [2,5,6].
Later, this disease also was found in other European coun-
tries, and in Asia and the USA [1]. A high prevalence of
urothelial carcinoma was found in aristolochic acid neph-
ropathy patients [3,7,8]. Animal models also demon-
strated that AA resulted in renal failure in rodents [9], and
tumors in the kidney, forestomach, and other tissues of
rats and mice [10-12]. AA was identified among the most
potent 2% of carcinogens [13]. The International Agency
for Research on Cancer (IARC) has classified the products
containing AA as human carcinogens [14].
Due to the toxicity of AA, the Food and Drug Administra-
tion (FDA) advised consumers to immediately discon-
tinue use of any botanical products containing AA and
published a list of botanical products that contained AA in
2001 [15]. Despite the FDA's warning, many products
containing or suspected to contain AA can still be identi-
fied on U.S. Web sites for sale for gastrointestinal symp-
toms, weight loss, cough, and immune stimulation [16].
AA is bioactivated and subsequently reacts with cellular
proteins and DNA, leading to multiple forms of toxicity.
AA is activated and produces DNA adducts in both kidney
and liver [17-20]. It, however, induces tumor only in kid-
ney although liver is the major organ for biotransforma-
tion of xenobiotics. The underlying mechanisms for the
tissue-specific carcinogenicity of AA are unknown.
The advent of gene microarrays permits the analysis of
gene expression patterns for thousands of genes simulta-
neously in biological samples of interest, providing new
insights into the effects of chemicals on biological systems
and allowing the macrodissection of molecular events in
chemical carcinogenesis. Identification of unique gene
expression patterns produced by carcinogens may allow
us to elucidate mechanisms of action. In this study, we
treated rats with a carcinogenic dose of AA and conducted
microarray analysis of gene expression in the kidney and
liver. To explore whether gene expression profiles can be
used for identifying AA exposure and to elucidate the tis-
sue-specific carcinogenicity of AA, clustering analysis,
functional analysis and biological process analysis were
performed on the gene expression profiles of kidney and
liver of rats treated with AA and the vehicle control. We
found that the gene expression profiles were significantly
altered by AA treatment in both kidney and liver, and
many more significant genes involved in cancer-related
pathways were found in kidney than in liver. Analysis of
biological process reveals that genes that are related to
apoptosis and immune response are largely altered by AA
treatment in kidney, but not in liver.
Results and Discussion
To investigate the effect of AA exposure on gene expres-
sion in the target tissue and non-target tissue, we treated
rats with a protocol similar to one that resulted in tumors
in rats [11]. Six-week-old rats were treated with 10 mg AA/
kg body weight five days a week for 12 weeks. One day
after the last treatment, 6 animals from the treated group
and 6 animals from the vehicle control group were sacri-
ficed, and the kidney (target tissue) and liver (non-target
tissue) were removed for the microarray analysis. In the
original carcinogenesis study [11], atypical cells and
hyperplasia were found in the kidney immediately after
cessation of AA treatment while adenomas and adenocar-
cinomas were not observed until three months after the
cessation of AA treatment. Because the sampling time in
the present study was one day after the three month treat-
ment, it is expected that many different stages of tumor
formation induced by AA will be present. The alteration of
gene expression profiles should reflect this process in kid-
ney and liver.
Principal component analysis and hierarchical cluster 
analysis group the samples according to tissues and AA 
treatment
Principal component analysis (PCA) was used to visualize
clusters of samples corresponding to the tissues and treat-
ment of AA based on variance-covariance structure of the
gene expressions in the 24 samples. PCA uses analysis of
the principal sources of variance in data and displays this
information graphically either 2-dimensionally or 3-
dimensionally [21]. A PCA 3D view using the first three
principal components for gene expression profiles from
the samples is displayed in Figure 1a. The PCA is based on
log2 intensity and the expression profiles are across 14361
genes whose signal intensities were greater than 150. The
captured variances of the first three components reached
74% of the total variance (Figure 1b), indicating the three
components were able to represent most of the expression
pattern of the individual samples. A hierarchical cluster
analysis (HCA) within ArrayTrack also was also used to
cluster the samples (Figure 2).
The PCA and HCA results demonstrate that samples were
grouped together according to the tissues and AA treat-
ment. The kidney samples were well separated from the
liver samples, suggesting a large difference betweenBMC Bioinformatics 2006, 7(Suppl 2):S20
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Principal component analysis (PCA) for gene expression profiles from kidney and liver of rats treated with aristolochic acid and  their concurrent controls Figure 1
Principal component analysis (PCA) for gene expression profiles from kidney and liver of rats treated with aristolochic acid and 
their concurrent controls. a) 3D view. The autoscaled method was used for the PCA. The red, blue, pink and green dots indi-
cate kidney control, kidney with aristolochic acid (AA) treatment, liver control, and liver with AA treatment, respectively. PC1, 
PC2, and PC3 represent first principal component, second principal component, and third principal component, respectively. 
b) Distribution of variance in principal components.
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Hierarchical clustering of samples according to gene expression profiles from kidney and liver of rats treated with aristolochic  acid and their concurrent controls Figure 2
Hierarchical clustering of samples according to gene expression profiles from kidney and liver of rats treated with aristolochic 
acid and their concurrent controls. Ward's Minimum Variance method was used. Labels K_AA, K_CTR, L_AA, and L_CTR 
indicate kidney with AA-treatment, kidney control, liver with AA-treatment and liver control, respectively.BMC Bioinformatics 2006, 7(Suppl 2):S20
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expression patterns of the two tissues. AA treatment
resulted in a clear alteration of gene expression in both
kidney and liver (Figures 1a and 2). These data suggest
that AA exposure in kidney and liver can be identified
based on gene expression profiles.
Genes associated with carcinogenesis were differentially 
regulated by AA treatment in kidney and liver
While the PCA and HCA show that AA treatment altered
the gene expression patterns, it does not reveal how many
genes and what kinds of genes are modulated and what
the differences are between kidney and liver. To this end,
the expression levels of genes in kidney and liver of rats
treated with AA were evaluated.
The differentially expressed genes between the treatment
and control (significant genes) were identified based on a
cutoff of p  < 0.01 and fold change > 1.5. Among the
26,857 genes, a total of 2172 and 2225 significant genes
were found, with 1063 and 914 genes down-regulated
and 1109 and 1311 genes up-regulated in kidney and
liver, respectively. When the kidney gene expression pro-
file was compared to the liver profile, 280 genes were
found to be commonly altered in both kidney and liver,
with most (204 genes) increasing or decreasing concord-
antly in the both tissues (Figure 3).
The different sets of genes that were significantly altered
by AA in kidney and liver were likely the results of tissue-
specific response to AA treatment and the different tissue-
specific suite of active genes present in those tissues. For
example, gene expression was very different between the
kidney and liver of control rats, with about 38% of genes
being differentially expressed (p < 0.01; fold change >1.5).
PCA and HCA results have also demonstrated the large
difference between expression patterns of the two tissues
(Figures 1 and 2). It would be expected that AA treatment
would impact the expression of some genes that are
uniquely expressed in the two tissues. Also, tissue-specific
response to AA exposure would produce different signifi-
cant genes. Rat kidney has been identified as a target tissue
for AA carcinogenesis while liver is a major site for AA
metabolism. It would be expected that more cancer-
related genes were altered by AA treatment in kidney than
in liver.
To compare the extent of the gene expression changes
caused by AA in kidney and liver, the significant genes
were grouped by fold-change (Table 1). There were more
significant genes with higher fold-changes in kidney than
in liver, indicating that AA treatment of the rats resulted in
greater changes in gene expression in kidney than in liver.
This difference might play an important role in the differ-
ential carcinogenicity and toxicity of AA in kidney and
liver.
The large number of significant genes resulting from AA
treatment in kidney and liver are expected to be the result
of different properties of AA, including pharmacological
and toxicological effects of this chemical. To identify the
genes related to carcinogenic effects of AA, we analyzed
the significant genes with Ingenuity Pathways Analysis
software (IPA, Ingenuity Systems, Redwood City, CA).
Functional analysis with IPA showed that there were
many more significant genes involved in cancer-related
pathways in kidney than in liver (Table 2). A total of 372
significant genes in kidney and 111 significant genes in
liver were involved in functions associated with different
stages of carcinogenesis. These functions included AA
metabolism, DNA repair, cell cycle, cellular development,
Table 1: Fold-changes of genes whose expression levels were 
altered significantly by aristolochic acid in kidney and liver.
Fold change Number of genes
Kidney Liver
> 10 29 16
5–10 95 34
2–5 1050 788
1.5–2 998 1387
Total 2172 2225
Venn diagram for genes whose expression was significantly  altered by aristolochic acid in kidney and liver Figure 3
Venn diagram for genes whose expression was significantly 
altered by aristolochic acid in kidney and liver. Gray, pink and 
yellow colors indicate genes whose expressions were altered 
in both kidney and liver, only kidney and only liver, respec-
tively.
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cell signaling, cellular growth and proliferation, cell mor-
phology, cell death, and tumor morphology.
Chemical carcinogenesis is a multistage process, with ini-
tiation, promotion and progression. Certain genes can be
involved in a specific carcinogenic process and their
expression changes can be indicative of the process. Due
to our chronic treatment schedule, many of the different
stages of AA carcinogenesis are expected to be detected at
our sampling time. The different number of genes associ-
ated with carcinogenesis between kidney and liver corre-
lates with the differential carcinogenicity of AA in the two
tissues.
Biological process analysis revealed that the defense 
response processes was significantly changed by AA 
exposure in kidney, but not in liver
Gene Ontology for Functional Analysis (GOFFA) within
ArrayTrack was developed at the National Center for Tox-
icological Research (NCTR), Jefferson, AR. This software
orders GO (gene ontology) terms by prevalence for a list
of selected genes or proteins, and then allows the user to
interactively select GO terms according to their signifi-
cance and specified biological complexity within the hier-
archical structure. GO has established a vocabulary that
provides a hierarchical structure for the analysis of
genome data and provides a classification of gene prod-
ucts into molecular functions, biological processes, and
cellular components [22] although GO curation of known
literature is incomplete and limited to gene function/
localization/process. GOFFA uses the GO database for
obtaining overviews of data and providing a rapid mech-
anism for researchers to classify genes that are often given
non-descriptive numerical names during genome annota-
tion. Significant gene lists were generated using criteria of
p < 0.01 and fold change > 2.0. These lists were directly
utilized for GOFFA analysis. Biological process in GOFFA
terms was examined for the genes from kidney and liver
individually. Terms that are significantly altered (p < 0.01)
are summarized in Table 3 and Table 4.
By comparing the alterations in biological processes in the
kidney and liver associated with AA exposure (Table 3 and
Table 4), it can be seen that the changes were very different
for these two tissues. These changes appear to be related to
different effects of AA on each tissue and the tissue-spe-
cific responses to AA. Most of the altered biological proc-
esses in liver were related to lipid metabolism including
steroid and other lipid metabolisms. Most of these genes
were up-regulated (Figure 4), which might result from the
pharmacological effects of AA because AA is an inhibitor
of phospholipase A 2 proteins that can hydrolyze phos-
pholipids to form fatty acid and lysophospholipid prod-
ucts. The most significantly changed processes associated
with AA exposure in kidney, however, were defense
response (including apoptosis and immune responses,
etc.) and organic acid metabolism (amino acid and car-
boxylic acid metabolisms, etc.). The genes in the pathways
for response to stress, toxin, biotic stimulus, tumor induc-
tion, and immune response were mainly up-regulated by
AA treatment (Figure 5) whereas the genes in the organic
acid metabolism were mainly down-regulated (Figure 6).
It is not unexpected that AA treatment triggers a strong
defense response in kidney considering that AA is a potent
nephrotoxin and kidney carcinogen [1,2,5,7]. Alteration
of immune response is a common biological reaction to
tissue damage, toxicity and tumors, while apoptosis is a
biological process that responds to toxicity, especially for
DNA damage. A large number of genes involved in these
processes can indicate the carcinogenic insults. AA-
induced apoptosis activities in cell culture and in tubular
cells of kidney have been reported [23-25] and tubular cell
apoptosis has been considered one of the mechanisms for
AA renal injury [26]. It has also been reported that AA can
induce mutations in the p53 and H-ras genes [1] that are
related to alteration of apoptosis [27-29]. The genes
involved in apoptosis were generally up-regulated to
remove the damaged cells caused by AA treatment. For
example, the inhba gene (first gene in the right panel of
Figure 5) whose expression increased 4.1-fold over the
control by AA treatment in kidney is a tumor-suppressor
gene and it produces a protein that increases growth arrest
in tumor cells [30]. Therefore, its induction in the kidney
by AA exposure may indicate a tissue response to genoto-
xic damage.
The reasons for the down-regulation of genes for organic
acid metabolism in kidney due to AA exposure are
unknown. A recent metabonomic study using urine and
blood samples from rats treated with AA [31] indicates
Table 2: Numbers of genes whose functions are related to 
carcinogenesis and whose expression was altered by aristolochic 
acid in kidney and liver of rats.
Functions Kidney Liver
Drug Metabolism 14 10
DNA replication, recombination and repair 2 4
Genetic disorder 17 6
Cell cycle 26 13
Cellular development 18 7
Cellular function and maintenance 16 5
Cell-to-cell and signaling and interaction 41 8
Cell morphology 36 15
Cell death 54 2
Cellular growth and proliferation 37 8
Tumor morphology 19 8
Cancer 92 25
Total 372 111
Note: the same genes may exist in different functions.BMC Bioinformatics 2006, 7(Suppl 2):S20
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Table 3: List of significant biological processes generated with GOFFA Terms in kidney of rats treated with aristolochic acid (p < 0.01).
Go term GO ID P value (Average) None of Genes Involved
Response to external stimulus GO:0009605 0.000000 55
Amino acid and derivative metabolism GO:0006519 0.000000 32
Organic acid metabolism GO:0006082 0.000000 45
Defense response GO:0006952 0.000000 57
Response to biotic stimulus GO:0009607 0.000000 59
Carboxylic acid metabolism GO:0019752 0.000000 45
Response to wounding GO:0009611 0.000000 40
Immune response GO:0006955 0.000001 50
Amino acid metabolism GO:0006520 0.000001 25
Amine metabolism GO:0009308 0.000001 32
Nitrogen compound metabolism GO:0006807 0.000002 33
Response to external biotic stimulus GO:0043207 0.000009 36
Response to stress GO:0006950 0.00002 64
Response to pest, pathogen or parasite GO:0009613 0.000024 34
Amino acid biosynthesis GO:0008652 0.000028 9
Induction of programmed cell death GO:0012502 0.000084 19
Induction of apoptosis GO:0006917 0.000084 19
Positive regulation of biological process GO:0048518 0.000162 48
Positive regulation of programmed cell death GO:0043068 0.000245 19
Positive regulation of apoptosis GO:0043065 0.000245 19
Amine biosynthesis GO:0009309 0.000247 11
Nitrogen compound biosynthesis GO:0044271 0.000247 11
Sulfur amino acid metabolism GO:0000096 0.000430 6
Generation of precursor metabolites and energy GO:0006091 0.000444 39
Complement activation, classical pathway GO:0006958 0.000645 6
Positive regulation of cellular process GO:0048522 0.000699 39
Positive regulation of physiological process GO:0043119 0.000849 37
Humoral defense mechanism (sensu Vertebrata) GO:0016064 0.000874 10
Positive regulation of cellular physiological process GO:0051242 0.000902 35
Regulation of programmed cell death GO:0043067 0.001275 27
Regulation of lymphocyte proliferation GO:0050670 0.001318 6
Regulation of immune response GO:0050776 0.001579 11
Amine catabolism GO:0009310 0.001671 9
Regulation of lymphocyte activation GO:0051249 0.001739 8
Regulation of apoptosis GO:0042981 0.002010 26
Amino acid catabolism GO:0009063 0.002152 8
Regulation of cell activation GO:0050865 0.002152 8
Nitrogen compound catabolism GO:0044270 0.002422 9
Sulfur metabolism GO:0006790 0.002637 8
Aspartate family amino acid metabolism GO:0009066 0.002692 4
Negative regulation of biological process GO:0048519 0.002726 45
Electron transport GO:0006118 0.002754 23
Cellular catabolism GO:0044248 0.002821 27
Xenobiotic metabolism GO:0006805 0.003190 6
that certain metabolic pathways involving organic acids,
such as homocysteine formation and the folate cycle, were
significantly accelerated while others, including arachi-
donic acid biosynthesis, were decreased. These alteration
has been associated with AA-induced nephrotoxicity [31].
Therefore, a number of genes involving amino acid and
carboxylic acid metabolisms might also be indicative of
AA-induced nephrotoxicity.
Conclusion
We analyzed gene expression profiles in kidney and liver
tissues of rats treated with AA and vehicle control by the
systematic approaches of PCA, functional analysis, and
biological process analyses. Our findings demonstrate
that AA treatment produced a significant alteration of
gene expression in both kidney and liver. The changes of
gene expressions induced in kidney and liver of rats, how-BMC Bioinformatics 2006, 7(Suppl 2):S20
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ever, were different, which may indicate tissue-specific
mechanisms of AA carcinogenicity. There were many
more significant genes associated with carcinogenesis in
kidney than in liver due to AA exposure. Significant
changes in biological processes related to defense
response, apoptosis and immune response, as well as
organic acid metabolism were found in kidney, but not in
liver. These differential alterations between kidney and
liver could be the underlying mechanisms for the tissue-
specific toxicity and carcinogenicity of AA.
Materials and methods
Animal and treatment
Big Blue transgenic Fisher 344 rats were obtained from
Taconic Laboratories (Germantown, NY). The transgenic
rats were chosen because the same animals were also uti-
lized for a study on mutagenicity of AA. We followed the
recommendations of the NCTR Institutional Animal Care
and Use Committee for the handling, maintenance, treat-
ment, and sacrifice of the rats.
Table 4: List of significant biological processes generated with GOFFA Terms in liver of rats treated with aristolochic acid (p < 0.01).
Go term GO ID P value (Average) Number of Genes Involved
Steroid metabolism GO:0008202 0.000000 16
Sterol metabolism GO:0016125 0.000000 12
Steroid biosynthesis GO:0006694 0.000000 13
Cholesterol biosynthesis GO:0006695 0.000000 9
Sterol biosynthesis GO:0016126 0.000000 11
Cellular lipid metabolism GO:0044255 0.000002 27
Lipid metabolism GO:0006629 0.000003 30
Terpenoid metabolism GO:0006721 0.000009 4
Polyisoprenoid metabolism GO:0016096 0.000009 4
Terpene metabolism GO:0042214 0.000009 4
Lipid biosynthesis GO:0008610 0.000012 15
Cholesterol metabolism GO:0008203 0.000021 9
Isoprenoid metabolism GO:0006720 0.000021 6
Isoprenoid biosynthesis GO:0008299 0.000059 4
Alkene metabolism GO:0043449 0.000147 5
Alcohol metabolism GO:0006066 0.000203 16
Xenobiotic metabolism GO:0006805 0.000830 5
Secondary metabolism GO:0019748 0.000830 5
Response to toxin GO:0009636 0.001363 4
Polyisoprenoid biosynthesis GO:0009241 0.001364 2
Pyrimidine deoxyribonucleotide metabolism GO:0009219 0.001364 2
Terpene biosynthesis GO:0046246 0.001364 2
Terpenoid biosynthesis GO:0016114 0.001364 2
Organic cation transport GO:0015695 0.001567 3
Response to xenobiotic stimulus GO:0009410 0.001584 5
Alkene biosynthesis GO:0043450 0.002440 3
Regulation of transferase activity GO:0051338 0.002531 8
Regulation of protein kinase activity GO:0045859 0.002531 8
Regulation of cyclin dependent protein kinase activity GO:0000079 0.002970 4
Cell growth GO:0016049 0.003636 9
Regulation of cell size GO:0008361 0.003939 9
Positive regulation of neuron differentiation GO:0045666 0.003992 2
Retinal metabolism GO:0042574 0.003992 2
Apocarotenoid metabolism GO:0043288 0.003992 2
Regulation of cell growth GO:0001558 0.004043 8
Regulation of growth GO:0040008 0.004604 9
Growth GO:0040007 0.005932 11
Hormone-mediated signaling GO:0009755 0.007789 2
Deoxyribonucleotide metabolism GO:0009262 0.007789 2
Response to hormone stimulus GO:0009725 0.007789 2
G2/M transition of mitotic cell cycle GO:0000086 0.007897 4
Electron transport GO:0006118 0.009494 13BMC Bioinformatics 2006, 7(Suppl 2):S20
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The treatment schedule was based on the previous carci-
nogenicity study [11]. Six 6-week-old male Big Blue rats
were treated with AA (Sigma, St. Louis, MO) as its sodium
salt at concentrations of 10 mg/kg body weight by gavage
(4 ml/kg body weight) five times a week for 12 weeks. Six
control rats were gavaged with the vehicle, 0.9% sodium
chloride, using the same schedule. The rats were sacrificed
one day after the last treatment; the kidneys and livers
were isolated, frozen quickly in liquid nitrogen, and
stored at -80°C.
RNA isolation and quality control
Total RNA from liver and kidney of the treated and con-
trol rats was isolated using an RNeasy system (Qiagen,
Valencia, CA). The yield of the extracted RNA was deter-
mined spectrophotometrically by measuring the optical
density at 260 nm. The quality of the extracted RNA was
evaluated using the RNA 6000 LabChip and Agilent 2100
Bioanalyzer (Agilent Technologies, Palo Alto, CA). Only
RNA with RNA integrity numbers (RINs) greater than 7.5
were used for microarray experiments. The microarray
analysis was performed using Applied Biosystems' Rat
Genome Survey Microarray with 26,857 gene probes.
Preparation of digoxigenin labeled cRNA
All RNA targets were labeled using the Applied Biosystems
RT-IVT Labeling Kit Version 2.0. Briefly, 1.5 μg of total
RNA sample was reverse transcribed by 2 h incubation at
42°C with ArrayScript RT™ enzyme (Ambion, Austin, TX)
and oligo dT-T7 primer. Double-stranded cDNA was pro-
duced following 2 h incubation with E. coli DNA polymer-
ase and RNase H at 16°C. The double-stranded cDNA was
purified using RT-IVT kit following the manufacturer's
protocol. The in vitro transcription was performed by
Significantly altered terms and the genes associated with lipid metabolism caused by AA treatment in rat liver Figure 4
Significantly altered terms and the genes associated with lipid metabolism caused by AA treatment in rat liver. The left panel is 
the Terms Window and the right panel is the Genes Window. The major genes in the list were up-regulated.BMC Bioinformatics 2006, 7(Suppl 2):S20
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incubation of the cDNA product with T7 RNA polymer-
ase, 0.75 mM Digoxigenin-11-UTP (Roche Applied Sci-
ence, Indianapolis, IN) and all other NTPs for 9 h. Labeled
cRNA was purified according to the RT-IVT kit protocol
and analyzed for quality and quantity using standard UV
spectrometry and the Bioanalyzer.
Hybridization of labeled cRNA to microarrays and 
microarray imaging
Digoxigenin labeled cRNA targets were hybridized to
Applied Biosystems Rat Whole Genome Survey Microar-
rays and detected using the Applied Biosystems Chemilu-
minescent Detection Kit. Briefly, 15 μg of labeled cRNA
targets were fragmented via incubation with fragmenta-
tion buffer provided in the kit for 30 min at 60°C. Frag-
mented targets were hybridized to microarrays during 16
h incubation at 55°C with buffers and reagents from the
Chemiluminescent Detection Kit. Post-hybridization
washes and anti-Digoxigenin-Alkaline Phosphatase bind-
ing were performed according to the protocol of the kit.
Chemiluminescence detection, image acquisition and
analysis were performed using Applied Biosystems
Chemiluminescence Detection Kit and Applied Biosys-
tems 1700 Chemiluminescent Microarray Analyzer fol-
lowing the manufacturer's protocols. Images were auto-
gridded and the chemiluminescent signals were quanti-
fied, corrected for background, and finally, spot- and spa-
tially-normalized using the Applied Biosystems 1700
Chemiluminescent Microarray Analyzer software version
1.1.
Normalization and statistic analysis
Gene expression data from the Applied Biosystems' Rat
Genome Survey Microarray were input to ArrayTrack for
Significantly altered terms and the genes associated with defense response caused by AA treatment in rat kidney Figure 5
Significantly altered terms and the genes associated with defense response caused by AA treatment in rat kidney. The left panel 
is the Terms Window and the right panel is the Genes Window. The major genes in the list were up-regulated.BMC Bioinformatics 2006, 7(Suppl 2):S20
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the management, analysis, visualization and interpreta-
tion of microarray data [32]. Raw microarray intensity
data were normalized per chip to the same median inten-
sity value of 500. The identification of differentially
expressed genes was based on permutation t-test. We eval-
uated several statistical methods to determine the signifi-
cant genes including Welch t-test, permutation t-test and
SAM (Significance Analysis of Microarrays [33]), all of
which yielded a set of similar significant genes. Since the
genes generated from permutation t-test covered 96% of
significant genes from Welch t-test and 97% significant
genes from SAM, permutation t-test was chosen for this
study. For the permutation tests, fullpermutations of 12
samples (6 for treatment and 6 for control) were per-
formed on the dataset of each tissue. The significant genes
were selected using cutoffs of p < 0.01 and fold change >
1.5.
Principal component analysis (PCA) and hierarchical 
cluster analysis (HCA)
PCA were conducted using the autoscaled method within
ArrayTrack [34]. The normalized data were converted into
log2 ratios and the data was filtered with signal intensity.
About 14361 genes (channel intensities > 150) in the
arrays were used for the PCA and HCA.
Functional analysis of the significant genes with IPA
Functional analysis of significant genes was performed
with IPA, a web-delivered software for discovering, visual-
izing, and exploring relevant functions, pathways and net-
works [35]. Significant genes were uploaded into IPA.
LocusID of each gene was mapped to its corresponding
gene object in the IPA Knowledge Base. A total of 911 out
of 2172 and 845 out of 2225 significant genes in kidney
and liver, respectively, were eligible for IPA analysis. These
Significantly altered terms and the genes associated with organic acid metabolism caused by AA treatment in rat kidney Figure 6
Significantly altered terms and the genes associated with organic acid metabolism caused by AA treatment in rat kidney. The 
left panel is the Terms Window and the right panel is the Genes Window. The major genes in the list were down-regulated.BMC Bioinformatics 2006, 7(Suppl 2):S20
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genes were then used as the starting point for generating
biological functions, pathways and networks. Biological
functions were calculated and assigned to different net-
works. Genes related to carcinogenesis were identified and
used for comparing the carcinogenic processes in kidney
and liver of rats treated with AA.
Analysis of Biological process with GOFFA
GOFFA software within ArrayTrack provides gene ontol-
ogy information using the standard vocabulary (terminol-
ogy) of the Gene Ontology Consortium. The ontology
provides standard vocabularies for the description of the
molecular function, biological process and cellular com-
ponent of gene products. ArrayTrack is freely available at
http://www.fda.gov/nctr/science/centers/toxicoinformat
ics/ArrayTrack/. Detailed descriptions of the GOFFA tool,
including the statistical analysis methods, are available in
the user's manual at the above web site. Lists of genes
whose expression was significantly altered in the kidney
or liver by AA exposure were generated using a gene selec-
tion cutoff of p < 0.01 and fold change > 2.0, GOFFA was
then used to analyze the biological processes affected by
AA treatment in liver and kidney. Significant biological
processes were selected from GOFFA Terms (p < 0.01) for
distinguishing differential response of kidney and liver to
AA exposure.
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